Nektar prices $325M stock offering at $92 per share

This financing is less about near-term runway and more about de-risking the path to a binary data stack. With a balance sheet that already looks ample, the incremental equity is effectively an insurance policy against having to fund Phase 3 from a weaker market window; that matters because biotech multiples typically compress hardest once the market shifts from "story stock" to "execution stock." The key second-order effect is that a well-capitalized NKTR can now force competitors in inflammatory disease to spend on differentiation rather than valuation arbitrage.

The supply overhang is not trivial: a large follow-on into a stock that has already rerated sharply can cap momentum for several weeks, especially if fast-money longs view the financing as a prompt to reduce gross exposure. But if management uses the cash to accelerate pivotal timelines, the overhang should fade into a catalyst stack over the next 6-18 months, and the market may start valuing rezpegaldesleukin more like a platform asset than a single-program readout. The market is likely underappreciating how much of the stock’s current multiple is being underwritten by optionality rather than fundamentals.

The contrarian risk is that the market is extrapolating positive Phase 2 signal into Phase 3 economics too quickly. In immune-dermatology, trial design, placebo response, and endpoint durability can compress apparent efficacy materially; if later studies show only modest separation, today’s capital raise will look like prudent balance-sheet management rather than proof of durable clinical franchise. Citigroup is a non-factor here; the actionable takeaway is that this is a financing-and-catalyst setup, not a broad repricing of the biotech group.